



External Quality Assessment Program for

Mycobacterium tuberculosis, rifampicin and isoniazid, nucleic acid detection

Labquality is announcing a new EQA scheme for *Mycobacterium tuberculosis*, rifampicin and isoniazid, nucleic acid detection. The scheme is suitable for nucleic acid test panels and scoring is based on the qualitative interpretation. Samples may contain strains of *M. tuberculosis* including rifampicin and/or isoniazid resistance and negative samples. Test panel selection will be taken in account when scoring.

The pilot round includes three samples that should be analysed as patient samples. The participants submit their results through the electronic platform LabScala and results are processed by the EQA Coordinator. Result evaluations including comments by the Scheme Expert will be published in the final report distributed to the participants.

Round 1, 2022 will be a pilot study free of charge for a limited number of participants. The pilot round will open in May/June. At least two rounds will be included in the program of 2023.

5230 *Mycobacterium tuberculosis*, rifampicin and isoniazid, nucleic acid detection

- Samples:** 2-3 artificial liquid samples, 1 mL each
Distribution: 1, 2022 May/June – pilot study free of charge
Participation: Limited number of samples available
Registration: Please register by **May 15th, 2022** via **this link**.

Please note, if you have already registered through the general pilot registration link earlier this year, no further actions are needed.

For more information

Labquality's customer service info@labquality.fi or

Jaana Paakkanen

EQA Coordinator

jaana.paakkanen@labquality.fi

+358 50 362 7719

Heidi Berghäll

Development Manager

heidi.berghall@labquality.fi

+358 50 356 0503